Investing.com - Financial Markets Worldwide

Carlyle Group plans to sell up to 10% stake in Piramal Pharma

Published 03/07/2025, 12:54
© Reuters.
CG
-1.18%
PIRM
-2.06%

Investing.com -- Private equity firm Carlyle Group (NASDAQ:CG) is preparing to sell up to a 10% stake in India’s Piramal Pharma, according to a report from Moneycontrol on Thursday.

The U.S.-based firm could earn between 26 billion rupees ($304.8 million) and 27 billion rupees from the sale, which would be conducted through block trades, the report said, citing sources.

As of March-end this year, Carlyle Group, through its affiliate Ca Alchemy Investments, held an 18% stake in Piramal Pharma, according to exchange data.

The private equity firm had originally acquired a 20% stake in the Indian drugmaker in 2020 for approximately $490 million, the Moneycontrol report added.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.